RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $103 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $103.
June 25, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $103, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and a maintained price target of $103 by RBC Capital suggests strong confidence in Intra-Cellular Therapies' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100